GA talking at Equity.Guruhttps://www.equity.guru/2016/12/20/podcast-ventripoint-diagnostics-vpt-v-ceo-gets-heart-matter/ Warning: The interview autoplays
Warning: Not all that useful for those who are already invested.
Warning: Interviewer throws softballs and GA hedges on the VPT's potential without more financing and the ability to validate all four chambers.
Summary (my takeaways):
A bunch of not much in the first 12 minutes
3:00 - Mentions in the process of filing with FDA, HC
12:00 - Regulatory clearance expected Q1 2017
12:30 - Was just at major conference in Europe - did 3 presentations
12:55 - Once the work on the left side is done, they will get users to publish results
16:20 - "Is this a value buy at this MC?" " Oh, yeah..."
[EDIT: oh, brother]
16:30 - Comparable companies are at 3,4,5x VPT's MC and they are only getting ready to submit to the FDA
[EDIT: FWIW, VPT was 10x+ current MC when in the process of submitting to FDA]
17:00 - 17 million has been invested in the tech
17:20 - GA states the MC should be in the 50-100 million range based on comparables but they struggled with the FDA and the medical community being brainwashed
[EDIT: Actually a good argument for Drs using VPT follows but too lazy to type it out.]
19:00 - There is an established insurance reimbursement code
19:50 - "Is the LV all that is needed?" "All four chambers will be needed, RV specialists are only a part of the decision making process"
20:30ish - The basis for the recent financiing was for regulatory approval and marketing.
21:00ish - They will need more. They are at the stage of an engine rev before the green light.
21:50 - The partner in China is well-funded. They should have the first "made-in-China" product by the end of the year. There are numerous hospitals in China waiting for it.
22:20 - They should be selling China starting in Q1 2017.
23:00 - "Will Q1 be key?" "We will first need to get a comprehensive solution with all 4 chambers
24:00ish - The units should sell (in USA?) for $75,000.
25:30 - They are getting interest from cancer drs as patients are starting to need heart scans prior to the next round of chemo.
27:30 - They would need 53 machines to reach the MC.
28:20 Discussion regarding the potential for a take-over. Established companies could be selling the product for 2x the price.
29:20 - More financing will be required to establish distribution based sales. 20 Machines would be needed to cover the cashflow.